High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma

Area of Science:

• Pediatric Oncology
• Medical Oncology
• Pharmacology

Background:

• Ewing's sarcoma presents a significant challenge in pediatric oncology.
• Previous chemotherapy regimens had limited efficacy in high-risk patients.
• The German Society of Pediatric Oncology (GPO) investigated novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy of high-dose ifosfamide (IFO) with mesna uroprotection in Ewing's sarcoma.
• To assess the combination of IFO and cisplatin in recurrent disease.
• To determine the effectiveness of the VAIA regimen (IFO, vincristine, actinomycin D, adriamycin) in first-line chemotherapy for high-risk newly diagnosed patients.

Main Methods:

• Phase II trials were conducted to assess IFO monotherapy and IFO-cisplatin combination therapy in recurrent Ewing's sarcoma.
• A new first-line chemotherapy regimen (VAIA) incorporating IFO was implemented for newly diagnosed, high-risk patients.
• Data from a pilot phase (1985) and an ongoing main trial (since 1986) were analyzed using Kaplan-Meier survival estimates.

Main Results:

• IFO monotherapy in recurrent disease yielded partial and complete responses.
• The IFO-cisplatin combination showed promising response rates in recurrent Ewing's sarcoma.
• The VAIA regimen demonstrated improved projected disease-free survival for patients with large primary tumors compared to the previous CESS 81 trial.
• Toxicity of the VAIA regimen was comparable to the conventional VACA regimen.

Conclusions:

• High-dose ifosfamide, particularly within the VAIA regimen, represents an effective treatment strategy for Ewing's sarcoma.
• The incorporation of IFO into first-line chemotherapy has improved outcomes for high-risk patients.
• The study supports the continued use and further investigation of ifosfamide-based chemotherapy in Ewing's sarcoma.